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 Phosphorylation and protonation of neighboring MiRP2 sites: function and 
pathophysiology of MiRP2-Kv3.4 potassium channels in periodic paralysis 
Geoffrey W. Abbott,* Margaret H. Butler,† and Steve A. N. Goldstein†,1 
*Greenberg Division of Cardiology, Department of Medicine and Department of Pharmacology, Cornell University, Weill 
Medical College, New York, New York, USA; and †Department of Pediatrics and The Institute of Molecular Pediatric Sciences, 
University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA 
 
ABSTRACT 
MinK-related peptide 2 (MiRP2) and Kv3.4 subunits assemble in skeletal muscle to create 
subthreshold, voltage-gated potassium channels. MiRP2 acts on Kv3.4 to shift the voltage dependence of 
activation, speed recovery from inactivation, suppress cumulative inactivation and increase unitary 
conductance. We previously found an R83H missense mutation in MiRP2 that segregated with periodic 
paralysis in two families and diminished the effects of MiRP2 on Kv3.4. Here we show that MiRP2 has a 
single, functional PKC phosphorylation site at serine 82 and that normal MiRP2-Kv3.4 function requires 
phosphorylation of the site. The R83H variant does not prevent PKC phosphorylation of neighboring S82; 
rather, the change shifts the voltage dependence of activation and endows MiRP2-Kv3.4 channels with 
sensitivity to changes in intracellular pH across the physiological range. Thus, current passed by single 
R83H channels decreases as internal pH is lowered (pKa ~7.3, consistent with histidine protonation) 
whereas wild-type channels are largely insensitive. These findings identify a key regulatory domain in 
MiRP2 and suggest a mechanistic link between acidosis and episodes of periodic paralysis.—Abbott, G.  
W., Butler, M. H., Goldstein, S. A. N. Phosphorylation and protonation of neighboring MiRP2 sites: 
function and pathophysiology of MiRP2-Kv3.4 potassium channels in periodic paralysis. FASEB J. 20, 
293–301 (2006) 
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Genes in the KCNE family encode single transmembrane (TM) domain peptides that do not function 
alone but coassemble with pore-forming potassium channel cx-subunits to form heteromeric complexes with 
the unique attributes of native potassium currents (1, 2). Thus, MinK (KCNE1) associates with KCNQ1 to 
form a complex whose attributes closely resemble the cardiac current IKs (3, 4); MinK-related peptide 1 
(MiRP1, encoded by KCNE2) assembles with HERG to pass currents like cardiac IKr (5) and MiRP2 
(KCNE3), the subject of the present study, associates with Kv3.4 to form a skeletal muscle potassium 
channel that activates at subthreshold membrane potentials (6). The necessity for KCNE peptides in native 
ion channels to achieve normal function is made apparent by their requirement to recapitulate the 
characteristics of native currents in heterologous expression studies and by genetic and biophysical evidence 
associating their alteration with human disease. Thus, missense mutations in KCNE1 and KCNE2 yield 
abnormal MiRPs that alter function and are associated with inherited and acquired long QT syndrome 
(LQTS), a cardiac arrhythmia that predisposes to sudden death (5, 7–11); KCNE3 is associated with 
periodic paralysis (PP) (6), a genetically and phenotypically mixed group of skeletal muscle disorders, 
characterized by episodic attacks of weakness or paralysis (12, 13). 
Disease-associated KCNE mutations identified to date reduce ability of channels to perform their 
normal role in repolarization due to diminished single channel conductance, a positive shift in the voltage 
dependence of activation, speeded deactivation, or a combination of these effects (6, 8, 14, 15). Some 
mutations are revealed clinically in response to a secondary, environmental stimulus. Thus, KCNE mutants 
associated with drug-induced arrhythmia include those with normal sensitivity to drug blockade (5, 16) and  
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 others with increased drug sensitivity (5). A common polymorphism associated with drug-induced 
arrhythmia manifests normal channel function that is altered only on drug exposure due to increased 
sensitivity to block (8). Analogously, a missense variant of the cardiac voltage-gated sodium channel that is 
common in African Americans, and linked with arrhythmia in aging adults (17) as well as sudden infant 
death syndrome, yields a channel that operates normally at baseline but shows abnormal gain-in-function 
with lowered intracellular pH (18). 
Here, we describe the influence of altered intracellular environment on normal and dysregulated 
function of MiRP2-Kv3.4 channels. We find that phosphorylation of serine 82 of MiRP2 (MiRP2-S82P) is 
required for MiRP2 to produce the normal shift in voltage-dependent activation of Kv3.4 observed in vivo. 
The mutation of neighboring arginine 83 to histidine (MiRP2-R83H), associated with periodic paralysis, is 
found to mimic the effect of S82 dephosphorylation even though the change does not prevent 
phosphorylation of S82. Finally, the R83H variant confers sensitivity to lowered pH, offering a molecular 
rationale for the onset of periodic paralysis during activities that produce intracellular acidosis. 
 
MATERIALS AND METHODS 
 
Molecular biology 
 
MiRP2 mutations were produced by pfu-based mutagenesis (QuickChange Kit; Stratagene, La Jolla, 
CA, USA) and confirmed by DNA sequencing. Human MiRP2 (acc no. AF076531) was cloned (5) and rat 
Kv3.4 (acc no. Q63734) was generously provided by B. Fakler (Tubingen). Genes were subcloned into 
pCINeo (Promega, Madison, WI, USA) for mammalian cell expression. A hemaglutinin (HA) epitope 
(sequence YPYDVPDYA) was inserted in the N terminus of MiRP2 to facilitate detection with anti-HA 
antibodies. 
 
Biochemistry 
 
COS-7 cells were cotransfected with Kv3.4 and HA-tagged wild-type or mutant MiRP2 constructs. 
Cells were harvested 48 h after transfection, solubilized at 4°C for 1 h in 200 mM KCl, 1% NP-40, 1% 
Triton X-100, 1% CHAPS, 0.1% SDS, 20 mM HEPES (pH 7.4) with protease inhibitors (Compete-EDTA 
free tablets; Roche, Basel, Switzerland). Lysates were cleared by centrifugation at 16,000 x g for 10 min at 
4°C, then passed through Sephadex G-25 to remove nucleotides into a solution of 200 mM KCl, 1% NP-40, 
1% Triton X-100, 1% CHAPS, 20 mM HEPES (pH 7.4),  and protease inhibitors. The following reagents 
were then added and the solution incubated at 30°C: 1 mM sodium orthovanadate, 100 nM calyculin A, 1 
µ,M cyclosporin A, 5 mM MgCl2, 5 mM ATP. After 30 min, 10 mM EDTA was added to terminate any 
phosphorylation reaction and the samples were placed on ice. MiRP2 was immunoprecipitated using 5 µ,g 
rat anti-HA antibody (Boehringer, Ingelheim, Germany) and protein G Sepharose (Pierce, Rockford, IL, 
USA). Samples were separated by SDS-PAGE (15% gels), followed by Western blot and detection of 
subunits by chemiluminesence using rabbit anti-phosphoserine antibody (Abcam, Cambridge, UK) or rabbit 
anti-HA antibody (Sigma, St. Louis, MO, USA) and HRP-conjugated secondary antibody. 
 
Electrophysiology 
 
For electrophysiology, Chinese hamster ovary (CHO) cells were transfected using Superfect 
(Qiagen, Valencia, CA, USA) with vectors carrying the cDNA for GFP, wild-type, or variant MiRP2 and 
Kv3.4. Currents were recorded by patch-clamp in cell-attached or off-cell, inside-out mode, 1–2 days after 
transfection. Recordings were obtained using an Axopatch 200A Amplifier (Axon Instruments, Foster City, 
CA, USA), an IBM computer and CLAMPEX software (Axon Instruments). Data analysis was performed 
using CLAMPFIT, FETCHAN, PSTAT (Axon Instruments) and TAC software (Instrutech, Great Neck, 
NY, USA). All recordings were performed at room temperature. Curves were fit to a Boltzmann function: 
1/{1 + exp[(V1/2-V)/Vs]}, where V1/2 is the half-maximal voltage of activation and Vs the slope factor. 
  
Protocols 
 
Holding voltage was – 80 mV unless otherwise stated. For quantification of the voltage dependence 
of activation, cells were held at – 80 mV and pulsed in 10 mV, 3 s steps between –100 and +90 mV with a 5 
s interpulse interval. For quantification of unitary current amplitude, cells were held at – 40 mV for 5–20 
min. 
 
Ionic conditions 
 
Pipette and bath solution for CHO cells in cell-attached mode was (in mM): 100 KCl, 0.7 MgCl2, 1 
CaCl2 , 10 HEPES (pH 7.4). Where appropriate, 10 nM phorbol-12-myristate-13 acetate (PMA) was 
included in the bath solution to stimulate PKC or 0.1 µ,M bis-indoylmaleimide (BIS) was included in the 
bath solution to inhibit PKC. For off-cell, inside-out recordings, pipette and bath solution were (in mM): 
100 KCl, 0.7 MgCl, 1 CaCl2; with 10 mM buffering agent that varied depending on pH range: MES, pH 6 – 
6.5; HEPES, pH 7– 8; PIPES, pH 8.5–9. 
 
RESULTS 
 
MiRP2-S82 is a phosphorylation site 
 
When identified in patients with periodic paralysis, MiRP2-R83H was studied and found to 
significantly alter the gating of MiRP2-Kv3.4 channels (6, 15). Specifically, wild-type MiRP2 shifts the 
midpoint voltage dependence of activation (V1/2act) of Kv3.4 channels to a subthreshold potential (~ – 40 
mV) while channels with R83H-MiRP2 show a suprathreshold value, V1/2act ~ –10 mV (15). Here, we 
explore the basis for the effect of the R83H mutation. Sequence analysis of human MiRP2 reveals that 
serine 82, neighboring R83, is within a predicted consensus protein kinase C (PKC) phosphorylation and 
that the site is conserved across the 5 members of the KCNE gene family (Fig. 1). We sought, therefore, to 
test the hypothesis that mutation at R83 altered function via an influence on the neighboring S82 
phosphorylation site. 
To determine if MiRP2 S82 is phosphorylated by PKC, COS cells were transfected with Kv3.4 and 
HA-tagged MiRP2 variants, for analysis by Western blotting using anti-phosphoserine antibodies. 
Following cell lysis and immunoprecipitation of wild-type MiRP2 (WT) using anti-HA, Western blot using 
anti-HA antibodies gave the expected bands (6) corresponding to the masses for the mature, immature and 
the carbohydrate-free glycosylation forms (Fig. 1C, lane 1). Western blotting using the anti-phosphoserine 
antibody revealed the same bands carried phosphoserine (Fig. 1D, lane 1). The same phosphoserine-positive 
bands were observed for MiRP2-R83H (Fig. 1D, lane 2) but not with MiRP2 variants, S82A and S82D, 
which remove the serine subject to phosphorylation (Fig. 1D, lanes 3 and 4). The results indicate that 
MiRP2 S82 can be phosphorylated by PKC, that this is the only MiRP2 site subject to modification, and that 
the R83H mutation does not prevent S82 phosphorylation. 
 
MiRP2-S82 phosphorylation is required for subthreshold activation 
 
The functional consequences of MiRP2 phosphorylation were assessed using patch clamp 
electrophysiology. Wild-type MiRP2-Kv3.4 channels readily reveal the most prominent influence of MiRP2 
under base-line conditions, to produce subthreshold activation, when studied in cell-attached patches with 
symmetrical potassium across the membrane; wild-type MiRP2- Kv3.4 channels show significant inward 
current compared to channels with Kv3.4 alone (Fig. 2A) (6). Compared to those with wild-type MiRP2, 
Kv3.4 channels with S82A-MiRP2, a variant that is not phosphorylated (Fig. 1D), exhibit much less inward 
current at negative potentials (Fig. 2A ). This is particularly noticeable by comparison of traces at – 40 mV 
(Fig. 2B, C) and suggests MiRP2 must bear phosphate to exert its full influence. Consistent with this 
 conclusion, wild-type MiRP2-Kv3.4 channels expressed in cells treated with PMA to stimulate PKC activity 
show prominent inward currents at – 40 mV while cells treated with BIS to inhibit PKC show reduced 
inward currents (Fig. 2D). Moreover, if phosphorylation of S82 mediates the effect, as expected, neither 
PMA nor BIS influence the operation of MiRP2-S82A-Kv3.4 channels (Fig. 2E ). Another argument for a 
role of phosphate on serine 82 in the effect of MiRP2 is recapitulation of the phosphorylated phenotype 
when a negative charge is permanently substituted at MiRP2 position 82; MiRP2-S82D-Kv3.4 channels 
show significant inward currents at – 40 mV (Fig. 2B, C) in a manner that is insensitive to both PMA and 
BIS exposure (not shown). 
Quantification of these effects (Table 1) shows that wild-type MiRP2-Kv3.4 channels in untreated 
cells activate with a V1/2act of ~– 40 mV, as before (6). This value was relatively unaffected by application of 
PMA, but was shifted to ~–10 mV by BIS application. S82A channels showed a V1/2 act of ~–10 mV 
regardless of PMA or BIS treatment. S82D MiRP2Kv3.4 channels behaved similarly to wild-type MiRP2-
Kv3.4 channels, with a V1/2 act of activation of ~– 40 mV. For comparison, Kv3.4 alone channels were also 
assessed, giving a V1/2act of +9 mV, again similar to previous observations (6). These results are consistent 
with wild-type channels being constitutively phosphorylated by PKC at S82 and thus active at subthreshold 
potentials, and why they are largely unaffected by PKC stimulation, but show altered activity when PKC is 
inhibited. When S82 is mutated to A, PKC can no longer regulate MiRP2 via S82 and thus S82A channels 
are unresponsive to both activators and inhibitors of PKC. Conversely, the S82D change is found to mimic 
the effect of S82 phosphorylation yielding subthreshold activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. MiRPs contain a conserved consensus PKC phosphorylation site. A) Sequence alignment of MinK and 
MiRPs 1-4, performed with ClustalW. Predicted transmembrane (TM) domain is boxed. The consensus PKC 
phosphorylation site is highlighted in gray, with the predicted phosphorylated serine asterisked. B) Predicted topology 
of MiRP2 in the plasma membrane showing positioning of S82 and R83. C) Western blot of immunoprecipitates 
probed with rabbit anti-HA antibody show protein production of wild-type (WT) and MiRP2 variants. COS-7 cells 
were cotransfected with Kv3.4 and HA-tagged wild-type, S82A, S82D, or R83H MIRP2. Cells were lysed, treated 
with phosphatase inhibitors ATP and Mg2+, and then immunoprecipitated with rat anti-HA antibody, and analyzed by 
Western blot. Blots were visualized with HRP-labeled secondary antibodies and chemiluminescence. Migration of 
molecular weight markers is indicated by numbers on left of gels (kDa). D) Same samples as in panel C, probed with 
anti-phosphoserine antibody showing phosphorylation of MiRP2 proceeds for WT and R83H but not the S82A or D 
variants 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. S82 phosphorylation is required for MiRP2 modulation of Kv3.4 gating. Studies of Kv3.4 channels alone or 
with wild-type (WT) or mutant MiRP2 performed in CHO cells in on-cell patch configuration with 100 mM KCl 
solution in bath and pipette using Protocol 1 (Materials and Methods). Data were collected at 5 kHz, digitally filtered 
at 1 kHz or 500 Hz. Exemplar cells expressing Kv3.4 alone, WT MiRP2-Kv3.4, and S82A-MiRP2-Kv3.4; current 
families recorded between –100 and 60 mV in patches with high channel density (inset, Protocol 1). Scale bars 30 pA 
(Kv3.4 alone) or 50 pA (with wild-type or S82A MiRP2) and 500 ms, dashed line represents zero current level. 
Exemplar traces recorded at +60 and – 40 mV from families recorded as in panel A, from channels formed by Kv3.4 
and wild-type, S82A or S82D MiRP2, with or without application of 0.1 µ,M bisindoylmaleimide (BIS) or 10 nM 
phorbol-12-myristate-13 acetate (PMA) as indicated. C) Normalized peak current voltage relationship for Kv3.4 
channels with no MiRP2 or with wild-type, S82A or S82D MiRP2; symbols as indicated. Error bars indicate se; n = 8 
–9 patches per group. Curves were fit to a Boltzmann function. D) Normalized peak current voltage relationship for 
wild-type MiRP2- Kv3.4 channels without (dashed line) or with (solid lines) application of 0.1 µ,M bisindoyl- 
maleimide (BIS) or 10 nM phorbol-12-myristate-13 acetate (PMA); symbols as indicated. Error bars indicate se; n = 8 
–11 patches per group. Curves were fit to a Boltzmann function. E) Normalized peak current voltage relationship for 
S82A MiRP2-Kv3.4 channels without or with application of 0.1 µ,M bisindoylmaleimide (BIS) or 10 nM phorbol- 
12-myristate-13 acetate (PMA); symbols as indicated. Error bars indicate se; n = 8 –14 patches per group. Curves 
were fit to a Boltz-mann function  
 
R83H channels show abnormal activation, regardless of S82 phosphorylation state 
 
R83H-MiRP2-Kv3.4 channels were shown to exhibit suprathreshold activation unlike wild-type 
MiRP2- Kv3.4 channels (6, 15). Here, we find that phosphorylation of S82 in wild-type MiRP2 is required 
to produce subthreshold activation (Fig. 2 and Table 1) and that R83H-MiRP2 is phosphorylated by PKC at 
 S82, arguing that failure to achieve subthreshold activation is not due to suppression of this event (Fig. 1C, 
D). Moreover, normal activation could not be restored in R83H channels by chemical or mutagenic addition 
of negative charge at S82. Thus, just as R83H-MiRP2 channels show suprathreshold activation (V1/2act ~–7 
mV) (Fig. 3A, B), so, too, a double mutant carrying both the S82P mimic S82D and R83H (S82D, R83H-
MiRP2) showed V1/2act ~–12mV (Fig. 3C). Furthermore, application of PMA to channels with R83H- 
MiRP2 had no significant effect on the voltage dependence of activation (Fig. 3A, C); application of BIS 
did shift V1/2act channels to –19 mV, ~10 mV more negative than the value for wild-type channels with BIS 
application. 
 
 
TABLE 1. Voltage dependence of activation of channels formed by Kv3.4 alone or with variants of MiRP2a 
  
 
The R83H mutation confers sensitivity to inhibition by lowered intracellular pH 
 
Lowered pH is a risk factor for some with periodic paralysis because attacks often occur with rest 
after exercise when serum and intracellular pH drop (19). Histidine can exist in both ionized and non-
ionized forms at neutral pH (pKa ~7) and can mediate pH sensitivity of proteins, including ion channels (20, 
21). The effects of altered intracellular pH (pHi) on wild-type and R83H-MiRP2-Kv3.4 single channels 
were therefore examined at – 40 mV using inside-out patches from CHO cells; previously, we observed that 
channels with R83H-MiRP2 display lower unitary conductance than those with wild-type at physiological 
pHi (15). 
While wild-type MiRP2-Kv3.4 channels showed little variation in unitary current amplitude over the 
range pHi 9.0 – 7.0, R83H-MiRP2-Kv3.4 complexes showed a steep decline across the physiological range 
(Fig. 4A). This effect was quantified by all-points histograms for each channel type at various pHi levels and 
construction of proton-inhibition curves (Fig. 4B–D). The pH dependence of current suppression for wild-
type MiRP2-Kv3.4 channels showed a half-maximal effect at ~ pHi 6.0, compared to ~ pHi 7.3 for R83H-
MiRP2-Kv3.4 complexes (Fig. 4C, D). Dropping to pHi 7.0 from 8.5 at – 40 mV reduced unitary current 
amplitude for channels with the R83H variant by 30% (to 1.20±0.21 pA from 1.70±0.14 pA) whereas wild-
type channel amplitudes were reduced just 5% (to 1.90±0.18 pA from 2.0±0.1 pA). Kv3.4 channels with no 
MiRP2 showed no significant sensitivity over the pHi range of 9.0 to 6.5 (Fig. 4C, D). 
 
 
TABLE 1. (continued) 
 
 
 
 
 DISCUSSION 
 
MiRP2-Kv3.4 channel gating is tightly controlled by PKC phosphorylation 
 
Wild-type MiRP2 shifts the potential for half-maximal activation of Kv3.4 channels ~ –50 mV (from 
V1/2act~+9 mV to – 40 mV, Table 1; ref 6) to create subthreshold-activating channels; the disease-associated 
point change R83H suppresses this influence of MiRP2 yielding complexes with V1/2act ~–10 mV (Table 1; 
ref 15). To assess the basis for this effect of R83H, we first studied neighboring S82, showing it to be an 
operational site for PKC phosphorylation, the only such site in the peptide, and to mediate the major effect 
of wild-type MiRP2 on Kv3.4 channels, that is, the ~ –50 mV shift in V1/2act. Mutation of MiRP2 S82 to A 
suppresses both phosphorylation of the peptide and its effects on Kv3.4 yielding V1/2act ~–7 mV. Further, an 
S82 to D mutation in MiRP2 allows it to serve like wild-type S82P MiRP2 yielding V1/2act ~– 42 mV. 
A key role for PKC in Kv3.4 is already known; this pore-forming cx subunit has an amino-terminal 
inactivation domain of ~28 amino acids containing two PKC sites where phosphorylation acts to alter 
secondary structure and impair inactivation (22–25). Thus, MiRP2-Kv3.4 channels can be regulated by 
action of PKC on both MiRP2 and Kv3.4 subunits, with phosphorylation leading to increased current due to 
activation at more negative potentials and reduced inactivation. 
 
A mechanistic link between lowered pHi and attacks of periodic paralysis 
 
To our surprise, the R83H change that suppressed the effects of S82 phosphorylation did not alter 
function by preventing phosphorylation of S82 or interfering with assembly of the MiRP2-Kv3.4 complexes 
(Fig. 1; ref 6). Moreover, the effect of R83H is dominant since subthreshold function is not restored to 
R83H-MiRP2- Kv3.4 channels by stimulation with PKC or MiRP2 double substitution (R83H, S82D-
MiRP2). However, while wild-type channels were relatively insensitive to changes in intracellular pH 
across the physiological range, R83H-MiRP2-Kv3.4 channels showed a significant decrease in current with 
lowered pHi. The most noticeable effect of the R83H mutation is the shift of ~–35 mV in activation voltage 
that decreases open probability at normal pH; lowering pHi further exacerbates this loss in function that may 
precipitate a clinical event. Although an S82 to D change mimics the effect of phosphorylated MiRP2 on 
Kv3.4 and suggests a negative charge is necessary and sufficient at the site, charge similarity does not 
appear adequate to restore native function to channels with R83H MiRP2, since lowered pH is likely to 
protonate the mutant histidine but further reduces similarity to wild-type. This suggests R83 may participate 
in important protein-protein contacts, perhaps with residues from Kv3.4. 
Attacks of hypokalemic familial PP often occur during rest after exercise (26, 27), as observed with 
one of our patients (6). While lowered serum potassium may be causative in these cases, another potential 
explanation is reduced pHi. During the first 5–10 s of exercise, metabolic alkalosis occurs apparently due to 
intracellular phosphocreatine hydrolysis, H+ efflux and H+ movement into sarcoplasmic reticulum (28 –33). 
Additional exercise leads to lower plasma and skeletal myocyte pH as lactic acid is produced, VO2 and local 
PCO2 increase, and H+ transport processes are reversed (28, 29, 31–33); acidosis facilitates oxygen 
dissociation from hemoglobin during exercise (31, 34). In mammalian skeletal muscle pHi is reported to 
drop below 6.5 with exercise: 6.28 was recorded in canine gracilis muscle after 3 min of exercise (28); 6.5 
was recorded in human gastrocnemius after 30 s of exercise (35); 6.4 was reported in human forearm after 
exercise to fatigue (36). Early in post-exercise recovery human muscle pHi is reported to become still lower 
(35, 36). Thus, protonation of a substituted histidine in MiRP2 position 83 provides a possible link between 
exercise, acidosis, and the onset of paralysis. At baseline, channels with R83H MiRP2 pass less current than 
wild-type and as pH drops below 7.0 another ~1/3 of the current (assessed at – 40 mV) will be lost. 
Although sustained weakness can occur in some individuals with age, attacks of paralysis are not 
permanent and often manifest with an environmental demand. This type of superimposition of genetic 
factors predisposing to risk with a secondary environmental challenge is analogous to the apparent 
mechanisms for some acquired cardiac arrhythmias where events occur due to diminished repolarization 
capacity at baseline, exacerbated by normal (8) or increased sensitivity to drug blockade (5). Particularly 
 relevant to this report is a missense variant in the cardiac voltage-gated sodium channel common in African 
Americans that operates normally at baseline but shows abnormal gain-in-function with lowered 
intracellular pH (18) and is linked to arrhythmia in aging adults (17) and sudden infant death syndrome (18). 
 
 
Figure 3. A negative charge at S82 does not restore subthreshold activation in R83H MiRP2-Kv3.4 channels. Studies 
of R83H or R83H, S82D MiRP2-Kv3.4 channels were performed in CHO cells in on-cell patch configuration with 
100 mM KCl solution in bath and pipette using Protocol 1 (Materials and Methods). Data were collected at 5 kHz, 
digitally filtered at 1 kHz or 500 Hz. A) Exemplar traces recorded at +60 and – 40 mV from families recorded 
between –100 and 60 mV in patches with high channel density (inset, Protocol 1) from channels formed by Kv3.4 and 
R83H or R83H, S82D MiRP2, with or without application of 0.1 µ,M bisindoylmaleimide (BIS) or 10 nM phorbol-
12-myristate-13 acetate (PMA) as indicated. B) Normalized peak current voltage relationship for channels formed 
with Kv3.4 and R83H-MiRP2 (filled circles) with curves for Kv3.4 with no MiRP2 (solid line) or wild-type MiRP2 
(dashed line) shown for comparison. Error bars indicate se; n = 9 –14 patches per group. Curves were fit to a 
Boltzmann function. C) Normalized peak current voltage relationship for R83H-MiRP2-Kv3.4 channels with 
application of 0.1 µ,M bisindoylmaleimide (BIS) or 10 nM phorbol-12-myristate-13 acetate (PMA); or R83H, S82D 
MiRP2- Kv3.4 channels; symbols as indicated. Error bars indicate se; n = 5– 8 patches per group. Curves were fit to a 
Boltzmann function. 
 
The sensitivity of R83H-MiRP2 channels to lowered pHi is also a possible explanation for 
apparently paradoxical results of treatment of some patients with the carbonic anhydrase inhibitor 
acetazolamide. While acetazolamide often decreases the frequency of PP attacks by causing metabolic 
acidosis and preventing intracellular potassium shifts (37), the agent can precipitate events in some (38). 
Thus, maintaining a normal pHi might prove more valuable in patients with R83H- MiRP2 than stabilizing 
intracellular potassium levels at the expense of pH. Acetazolamide slows the rate of recovery of normal 
 intracellular pH during rest after exercise and reduces the absolute pH reached during exercise and recovery 
(36). This draws comparisons to treatment of cardiac arrhythmia, where some anti-arrhythmic drugs are pro-
arrhythmic due to blockade of cardiac delayed rectifier potassium channels, especially IKr (8). 
 
R83H-MiRP2 and linkage to PP 
 
Periodic paralysis is a genetically and phenotypically heterogeneous group of episodic skeletal 
muscle disorders characterized by prolonged episodic attacks of weakness or paralysis (12, 39). Given the 
overlap of symptoms, and as different forms of PP are associated with mutations in several skeletal muscle 
ion channel genes, a useful classification will be one based on genotyping (12, 40) both as a strategy to 
target optimal therapy and avoid complications like those described above for acetazolamide. 
PP has been associated with mutations in the L-type calcium channel gene (CACNLA3) (41, 42), the 
voltage-gated sodium channel gene (SCN4A) (43– 47), and MiRP2 (KCNE3) (6). The related muscle 
disorder myotonia congenita is linked to mutations in a chloride channel gene (CLCN1) (48, 49). 
Andersen’s syndrome, a disorder in which patients present with developmental defects, cardiac arrhythmia, 
and periodic paralysis, is caused by mutation of the inward rectifier potassium channel gene KCNJ7 (50). 
After the original report of association of KCNE3 mutation with PP (6), linkage of R83H-MiRP2 has been 
questioned based on observations of the genotype in 3 of 320 controls and a family with PP where it did not 
segregate with disease, although, that kindred had another mutation to explain the disease (51). We found 
the R83H variant in two small pedigrees in all individuals with PP and not in unaffected relatives, and did 
not observe the variant in 100 controls (6). This was suggestive for association with disease, but it was the 
functional effects of the amino acid change that made the case for linkage so strong (6). The possibility 
remains that R83H is predisposing for PP and must be present with some other genetic variant (such as a 
promoter variant that leads to a higher level of the R83H allele or changes the operation of some other 
protein); in that case, cosegregation in our kindreds could be because of linkage to the additional change or 
coincidence. The current report suggests that R83H-MiRP2 subunits might predispose to PP by creating 
channels that are sensitive to lowered intracellular pH, yielding a secondary challenge to normal muscle 
function from a common change in acid-base status in response to intense exercise. The data supporting the 
conclusion that R83H is a periodic paralysis gene are compelling: occurrence in patients from two affected 
families, presence of message and protein in the appropriate human tissue, interaction of MiRP2 with Kv3.4 
in rat and mouse muscle, functional effects of assembly of the subunits, functional changes on expression of 
the mutation in muscle cells consistent with disease, and a mechanistic link between dysfunction of R83H-
MiRP2-Kv3.4 channels and a known precipitating agent in some cases of PP, intracellular acidosis. 
 
A KCNE domain critical to gating and conduction 
 
The membrane-following region of MiRP2 contains a number of features highly conserved among 
KCNE peptides: a cluster of basic residues, a consensus protein kinase C (PKC) phosphorylation site, and a 
conserved aspartic acid (position 90 in MiRP2) (1). The basic residues are present in all five known KCNE 
peptides; the aspartic acid is conserved in MinK (D76), MiRP1 (D82), MiRP2 (D90) and MiRP4 (D92). In 
MinK and MiRP2 a D-N mutation at this position causes reduced unitary conductance and altered 
gating; in MinK this mutation causes Romano-Ward and Jervell and Lange-Nielsen syndromes (manifesting 
cardiac arrhythmia without and with sensorineural deafness, respectively) (10, 14, 15). Mutation of nearby 
S74 to L in MinK also reduces current density and is associated with cardiac arrhythmia (10, 14). 
Like R83 in MiRP2, MinK and MiRP1 contain lysine in the analogous site and mutant changes have 
similar effects. Thus, R83H-MiRP2, K69H-MinK, and K75H- MiRP1 have blunted effects compared with 
wild-type on cx-subunits in the resultant IKs and IKr channels (15). Further, R83H in MiRP2 affects not only 
complexes with Kv3.4 but the properties of MiRP2/KCNQ1 and MiRP2/HERG channels (15). While 
channel function is sensitive to changes in this conserved region, it should be noted that mutations do not  
  
Figure 4. The R83H mutation in MiRP2 increases sensitivity to low pH of MiRP2/Kv3.4 channels. Studies of Kv3.4 
with or without wild-type or R83H-MiRP2 single channel currents expressed in CHO cells were performed in inside-
out patches with varying “internal” pH as indicated at – 40 mV with 100 mM KCl solution in the bath and pipette. 
Data were collected at 5 kHz, low-pass filtered at 500 Hz. A) Exemplar single channel current recordings from 
channels formed by Kv3.4 and wild-type (WT) or R83H-MiRP2, at pH 6.5, 7.5 and 8.5. Dashed lines indicate wild-
type open state level (“o”) and closed state (“c”). Scale bars indicate 1 pA and 100 ms. B) Representative all-points 
histograms from recordings at “intracellular” pH 6.5, 7.5 and 8.5, for single WT MiRP2-Kv3.4 (open squares) and 
R83H-MiRP2-Kv3.4 (filled circles) channels; histogram for homomeric Kv3.4 (filled squares) channels shown for 
comparison. C) Mean unitary current amplitudes at – 40 mV in a range of intracellular pH values between 6 and 9 for 
WT (open squares) and R83H (filled circles) MiRP2-Kv3.4 channels, or homomeric Kv3.4 channels (filled squares) 
calculated using all-points histograms as in panel B (n=3–5 patches per point), error bars indicate se. Curves were fit 
to the function: y = [A1-A2 / {1+(x/x0)p}]+A2 , where x = pH, x0 = the inhibition constant, and p = the Hill coefficient. 
WT MiRP2/Kv3.4 channels: A1 = 0.91 ± 0.15, A2 = 2.1 ± 0.08, x0 = 6.0 ± 1.7, P = 0.70 ± 0.25; R83H-MiRP2-Kv3.4 
channels: A1 = 1.0 ± 0.06, A2 = 1.7 ± 0.04, x0 = 7.3 ± 0.11, P = 0.33 ± 0.1; homomeric Kv3.4 channels: A1 = 0.78 ± 
0.28, A2 = 1.3 ± 0.05, x0 = 5.2 ± 59, P = 0.35 ± 2.5. D) Mean normalized unitary current amplitudes at – 40 mV in a 
range of intracellular pH values for WT (open squares) and R83H (filled circles) MiRP2-Kv3.4 channels, or 
homomeric Kv3.4 channels (filled squares) as in panel B; values normalized to unitary current amplitudes at pH 9.0. 
Curves were fit to the function: y = [A1-A2 /{1+(x/x0)p}] + A2 , where x is pH, x0 the inhibition constant and p the Hill 
coefficient. WT MiRP2-Kv3.4 channels: A1 = 0.53 ± 0.06, A2 = 1.0 ± 0.03, x0 = 6.2 ± 0.1, P = 0.62 ± 0.21; R83H-
MiRP2-Kv3.4 channels: A1 = 0.58 ± 0.04, A2 = 1.0 ± 0.02, x0 = 7.3 ± 0.11, P = 0.34 ± 0.12; homomeric Kv3.4 
channels: A1 = 0.26 ± 0.83, A2 = 1.1 ± 0.06, x0 = 5.2 ± 59.2, P = 0.44 ± 4.0 
 
have effects in all MiRP-cx subunit complexes; R83H–MiRP2 does not disrupt function of complexes 
formed by MiRP2 and Kv2.1 or Kv3.1, perhaps because in these complexes MiRP2 alters the rate but not 
the voltage dependence of activation (52). Future studies addressing how this critical MiRP region interacts 
with pore-forming subunits should yield insight into normal function and mechanisms of inherited and 
 acquired human disease. 
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